Lixisenatide non-inferior to exenatide for diabetes

Lixisenatide non-inferior to exenatide for diabetes
In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according to a study published online May 22 in Diabetes Care.

(HealthDay)—In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according to a study published online May 22 in Diabetes Care.

Julio Rosenstock, M.D., from the Dallas Diabetes and Endocrine Center at Medical City, and colleagues randomly assigned 634 adults whose type 2 diabetes was not adequately controlled with metformin ( [HbA1c], 7 to 10 percent) to 20 µg lixisenatide once daily or 20 µg exenatide twice daily.

After 24 weeks, the researchers found that lixisenatide once daily was non-inferior to exenatide twice daily in terms of least squares mean change in HbA1c, responder rate (HbA1c <7.0 percent), and improvements in fasting plasma glucose, although weight loss in the lixisenatide group was lower. The lixisenatide group had a significantly lower proportion with symptomatic hypoglycemia (2.5 versus 7.9 percent) and a significantly lower proportion with gastrointestinal events (24.5 versus 35.1 percent). The incidence of adverse events and serious adverse events were similar for both drugs.

"Add-on lixisenatide once daily in inadequately controlled with metformin demonstrated non-inferior improvements in HbA1c, with slightly lower mean weight loss, lower incidence of hypoglycemia, and better gastrointestinal tolerability compared with exenatide twice daily," Rosenstock and colleagues conclude.

The study was funded by Sanofi; several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Sanofi.


Explore further

Most youth with type 1 diabetes don't meet HbA1c goals

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: Lixisenatide non-inferior to exenatide for diabetes (2013, June 7) retrieved 22 October 2020 from https://medicalxpress.com/news/2013-06-lixisenatide-non-inferior-exenatide-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments